Clinical Trial

A Phase 2 Clinical Study of ABSK061 and ABSK043

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-07.
Status change: Not Yet Recruiting → Recruiting 2024-11-18
Trial Details
NCT Number NCT06632262
Lead Sponsor Abbisko Therapeutics Co, Ltd
Conditions HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
Enrollment 202 participants
Start Date 2024-11-13
Primary Completion 2029-11-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-19